Allogene Therapeutics (ALLO) Stock Forecast, Price Target & Predictions
ALLO Stock Forecast
Allogene Therapeutics stock forecast is as follows: an average price target of $29.00 (represents a 879.73% upside from ALLO’s last price of $2.96) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
ALLO Price Target
The average price target for Allogene Therapeutics (ALLO) is $29.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $7.00. This represents a potential 879.73% upside from ALLO's last price of $2.96.
ALLO Analyst Ratings
According to 8 Wall Street analysts, Allogene Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ALLO stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 0 'Hold' (0.00%), 1 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).
Allogene Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 16, 2024 | Debjit Chattopadhyay | H.C. Wainwright | $9.00 | $2.98 | 202.01% | 204.05% |
| May 14, 2024 | Kalpit Patel | B.Riley Financial | $7.00 | $2.90 | 141.38% | 136.49% |
| Jun 13, 2022 | Jack Allen | Robert W. Baird | $11.00 | $9.74 | 12.94% | 271.62% |
| Jan 03, 2022 | Michael Schmidt | Guggenheim | $35.00 | $15.29 | 128.91% | 1082.43% |
| Dec 03, 2021 | John Newman | Canaccord Genuity | $55.00 | $17.62 | 212.15% | 1758.11% |
| Oct 08, 2021 | Anthony Butler | Roth Capital | $35.00 | $13.13 | 166.57% | 1082.43% |
| Oct 08, 2021 | Jason Gerberry | Bank of America Securities | $32.00 | $13.13 | 143.72% | 981.08% |
| Oct 08, 2021 | Mark Breidenbach | Oppenheimer | $40.00 | $13.13 | 204.65% | 1251.35% |
| Oct 08, 2021 | Biren Amin | Jefferies | $30.00 | $13.13 | 128.48% | 913.51% |
| Sep 23, 2021 | Dane Leone | Raymond James | $36.00 | $27.64 | 30.25% | 1116.22% |
The latest Allogene Therapeutics stock forecast, released on May 16, 2024 by Debjit Chattopadhyay from H.C. Wainwright, set a price target of $9.00, which represents a 202.01% increase from the stock price at the time of the forecast ($2.98), and a 204.05% increase from ALLO last price ($2.96).
Allogene Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $8.00 |
| Last Closing Price | $2.96 | $2.96 | $2.96 |
| Upside/Downside | -100.00% | -100.00% | 170.27% |
In the current month, the average price target of Allogene Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Allogene Therapeutics's last price of $2.96. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2024 | Citigroup | Buy | Buy | Hold |
| Jun 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 31, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| May 31, 2024 | Piper Sandler | - | Overweight | Initialise |
| May 21, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 15, 2024 | RBC Capital | Buy | Buy | Hold |
| Jan 06, 2023 | Robert W. Baird | - | Outperform | Upgrade |
| Dec 13, 2022 | Bank of America Securities | - | Reduce | Downgrade |
| Jul 15, 2022 | Goldman Sachs | - | Buy | Upgrade |
Allogene Therapeutics's last stock rating was published by Citigroup on Aug 09, 2024. The company gave ALLO a "Buy" rating, the same as its previous rate.
Allogene Therapeutics Financial Forecast
Allogene Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $43.00K | $44.00K | $52.00K | $47.00K | $49.00K | - | $61.00K | $51.00K | $49.00K | $44.00K | $38.34M | - | - |
| Avg Forecast | $5.00K | $5.00K | $4.54K | $4.54K | $1.08M | $10.00K | $2.01M | $11.23K | $22.00K | $14.46K | $13.47K | $8.92K | $77.18K | $12.38K | $8.33K | $-7.69K | $-7.69K | $263.86K | $13.92M | $13.92M | $2.71M | $224.15K |
| High Forecast | $5.00K | $5.00K | $4.54K | $4.54K | $1.08M | $12.50K | $2.01M | $11.23K | $22.00K | $14.46K | $13.47K | $8.92K | $77.18K | $12.38K | $8.33K | $-5.77K | $-5.77K | $329.82K | $17.39M | $17.39M | $3.25M | $268.98K |
| Low Forecast | $5.00K | $5.00K | $4.54K | $4.54K | $1.08M | $7.50K | $2.01M | $11.23K | $17.60K | $14.46K | $13.47K | $8.92K | $77.18K | $12.38K | $8.33K | $-9.62K | $-9.62K | $197.89K | $10.44M | $10.44M | $2.17M | $179.32K |
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 5 | 5 | 6 | 12 | 11 | 10 | 13 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.97% | 3.27% | 5.83% | 0.61% | 3.96% | - | -7.93% | -6.63% | 0.19% | 0.00% | 2.76% | - | - |
Allogene Therapeutics's average Quarter revenue forecast for Dec 23 based on 9 analysts is $22.00K, with a low forecast of $17.60K, and a high forecast of $22.00K. ALLO's average Quarter revenue forecast represents a -48.84% decrease compared to the company's last Quarter revenue of $43.00K (Sep 23).
Allogene Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 5 | 5 | 6 | 12 | 11 | 10 | 13 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-62.98M | $-80.52M | $-99.07M | $-96.37M | $-78.63M | - | $-76.30M | $-70.63M | $-75.86M | $-68.97M | $-31.10M | $-66.73M | $-59.09M |
| Avg Forecast | $-999.00 | $-999.00 | $-908.00 | $-908.00 | $-216.28K | $-2.00K | $-402.15K | $-94.71M | $-4.40K | $-2.89K | $-2.69K | $-86.10M | $-15.44K | $-69.66M | $-1.67K | $-78.28M | $-77.69M | $-74.50M | $-71.48M | $-40.76M | $-62.68M | $-62.40M |
| High Forecast | $-999.00 | $-999.00 | $-908.00 | $-908.00 | $-216.28K | $-1.50K | $-402.15K | $-75.77M | $-3.52K | $-2.89K | $-2.69K | $-68.88M | $-15.44K | $-55.73M | $-1.67K | $-62.62M | $-62.15M | $-59.60M | $-57.18M | $-32.61M | $-50.15M | $-49.92M |
| Low Forecast | $-999.00 | $-999.00 | $-908.00 | $-908.00 | $-216.28K | $-2.50K | $-402.15K | $-113.66M | $-4.40K | $-2.89K | $-2.69K | $-103.32M | $-15.44K | $-83.59M | $-1.67K | $-93.93M | $-93.23M | $-89.40M | $-85.78M | $-48.92M | $-75.22M | $-74.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | 21775.59% | 29899.00% | 1.15% | 6243.46% | 1.13% | - | 0.97% | 0.91% | 1.02% | 0.96% | 0.76% | 1.06% | 0.95% |
undefined analysts predict ALLO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Allogene Therapeutics's previous annual EBITDA (undefined) of $NaN.
Allogene Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 5 | 5 | 6 | 12 | 11 | 10 | 13 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | $-61.31M | $-77.99M | $-98.34M | $-93.32M | $-82.15M | - | $-79.71M | $-74.87M | $-78.19M | $-70.94M | $-33.02M | $-68.57M | $-60.97M |
| Avg Forecast | $-72.56M | $-71.17M | $-70.63M | $-70.78M | $-66.00M | $-62.42M | $-66.50M | $-99.95M | $-85.66M | $-98.72M | $-111.89M | $-90.86M | $-132.94M | $-71.80M | $-97.88M | $-82.60M | $-82.35M | $-76.79M | $-73.52M | $-43.28M | $-72.24M | $-62.10M |
| High Forecast | $-72.56M | $-71.17M | $-70.63M | $-70.78M | $-66.00M | $73.57M | $-66.50M | $-79.96M | $-67.43M | $-98.72M | $-111.89M | $-72.69M | $-132.94M | $-57.44M | $-97.88M | $-66.08M | $-65.88M | $-61.43M | $-58.81M | $-34.62M | $-57.79M | $-49.68M |
| Low Forecast | $-72.56M | $-71.17M | $-70.63M | $-70.78M | $-66.00M | $-84.72M | $-66.50M | $-119.94M | $-109.35M | $-98.72M | $-111.89M | $-109.04M | $-132.94M | $-86.16M | $-97.88M | $-99.12M | $-98.83M | $-92.15M | $-88.22M | $-51.93M | $-86.69M | $-74.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.62% | 0.70% | 1.08% | 0.70% | 1.14% | - | 0.96% | 0.91% | 1.02% | 0.96% | 0.76% | 0.95% | 0.98% |
Allogene Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALLO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Allogene Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 5 | 5 | 6 | 12 | 11 | 10 | 13 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | $17.04M | $18.52M | $18.88M | $21.00M | $18.90M | - | $19.90M | $19.96M | $19.00M | $18.78M | $16.36M | $17.13M | $15.86M |
| Avg Forecast | $1.08M | $1.08M | $986.02K | $986.02K | $234.61M | $2.17M | $436.22M | $2.44M | $4.77M | $3.14M | $2.92M | $1.93M | $16.74M | $2.69M | $1.81M | $-1.67M | $-1.67M | $57.24M | $3.02B | $3.02B | $587.93M | $48.63M |
| High Forecast | $1.08M | $1.08M | $986.02K | $986.02K | $234.61M | $2.71M | $436.22M | $2.44M | $4.77M | $3.14M | $2.92M | $1.93M | $16.74M | $2.69M | $1.81M | $-1.25M | $-1.25M | $71.55M | $3.77B | $3.77B | $705.51M | $58.35M |
| Low Forecast | $1.08M | $1.08M | $986.02K | $986.02K | $234.61M | $1.63M | $436.22M | $2.44M | $3.82M | $3.14M | $2.92M | $1.93M | $16.74M | $2.69M | $1.81M | $-2.09M | $-2.09M | $42.93M | $2.26B | $2.26B | $470.34M | $38.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | 5.43% | 6.34% | 9.76% | 1.25% | 7.03% | - | -11.92% | -11.96% | 0.33% | 0.01% | 0.01% | 0.03% | 0.33% |
Allogene Therapeutics's average Quarter SG&A projection for Dec 23 is $4.77M, based on 9 Wall Street analysts, with a range of $3.82M to $4.77M. The forecast indicates a -71.99% fall compared to ALLO last annual SG&A of $17.04M (Sep 23).
Allogene Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 5 | 5 | 6 | 12 | 11 | 10 | 13 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.37 | $-0.53 | $-0.68 | $-0.65 | $-0.57 | - | $-0.56 | $-0.54 | $-0.57 | $-0.53 | $-0.25 | $-0.53 | $-0.53 |
| Avg Forecast | $-0.38 | $-0.37 | $-0.37 | $-0.37 | $-0.35 | $-0.33 | $-0.35 | $-0.41 | $-0.45 | $-0.52 | $-0.59 | $-0.62 | $-0.70 | $-0.61 | $-0.58 | $-0.60 | $-0.56 | $-0.55 | $-0.46 | $-0.57 | $-0.54 | $-0.58 |
| High Forecast | $-0.38 | $-0.37 | $-0.37 | $-0.37 | $-0.35 | $0.39 | $-0.35 | $-0.41 | $-0.35 | $-0.52 | $-0.59 | $-0.62 | $-0.70 | $-0.61 | $-0.58 | $-0.40 | $-0.38 | $-0.37 | $-0.31 | $-0.39 | $-0.37 | $-0.39 |
| Low Forecast | $-0.38 | $-0.37 | $-0.37 | $-0.37 | $-0.35 | $-0.45 | $-0.35 | $-0.41 | $-0.58 | $-0.52 | $-0.59 | $-0.62 | $-0.70 | $-0.61 | $-0.58 | $-0.79 | $-0.74 | $-0.72 | $-0.61 | $-0.76 | $-0.72 | $-0.77 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.71% | 0.90% | 1.10% | 0.93% | 0.94% | - | 0.94% | 0.97% | 1.04% | 1.15% | 0.44% | 0.98% | 0.92% |
According to undefined Wall Street analysts, Allogene Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALLO previous annual EPS of $NaN (undefined).
Allogene Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SGMO | Sangamo Therapeutics | $0.85 | $12.00 | 1311.76% | Hold |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| ALLO | Allogene Therapeutics | $2.96 | $29.00 | 879.73% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| NTLA | Intellia Therapeutics | $22.07 | $119.16 | 439.92% | Buy |
| EDIT | Editas Medicine | $3.95 | $17.00 | 330.38% | Buy |
| PRME | Prime Medicine | $4.09 | $17.25 | 321.76% | Buy |
| VERV | Verve Therapeutics | $5.50 | $21.50 | 290.91% | Buy |
| HRTX | Heron Therapeutics | $1.87 | $7.00 | 274.33% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| BEAM | Beam Therapeutics | $26.30 | $64.20 | 144.11% | Buy |
| ITOS | iTeos Therapeutics | $16.70 | $38.50 | 130.54% | Buy |
| ANNX | Annexon | $7.20 | $14.00 | 94.44% | Buy |
| CRBU | Caribou Biosciences | $2.12 | $3.00 | 41.51% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| GTHX | G1 Therapeutics | $7.15 | $4.50 | -37.06% | Buy |
ALLO Forecast FAQ
Is Allogene Therapeutics a good buy?
Yes, according to 8 Wall Street analysts, Allogene Therapeutics (ALLO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of ALLO's total ratings.
What is ALLO's price target?
Allogene Therapeutics (ALLO) average price target is $29 with a range of $7 to $55, implying a 879.73% from its last price of $2.96. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Allogene Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ALLO stock, the company can go up by 879.73% (from the last price of $2.96 to the average price target of $29), up by 1758.11% based on the highest stock price target, and up by 136.49% based on the lowest stock price target.
Can Allogene Therapeutics stock reach $4?
ALLO's average twelve months analyst stock price target of $29 supports the claim that Allogene Therapeutics can reach $4 in the near future.
What are Allogene Therapeutics's analysts' financial forecasts?
Allogene Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $3.11M (high $3.12M, low $3.11M), average EBITDA is $-95.333M (high $-76.39M, low $-114M), average net income is $-295M (high $-139M, low $-337M), average SG&A $675.44M (high $675.98M, low $674.9M), and average EPS is $-1.435 (high $-0.72, low $-1.553). ALLO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $19.09K (high $19.09K, low $19.09K), average EBITDA is $-3.814K (high $-3.814K, low $-3.814K), average net income is $-285M (high $-285M, low $-285M), average SG&A $4.14M (high $4.14M, low $4.14M), and average EPS is $-1.501 (high $-1.501, low $-1.501).
Did the ALLO's actual financial results beat the analysts' financial forecasts?
Based on Allogene Therapeutics's last annual report (Dec 2023), the company's revenue was $95K, beating the average analysts forecast of $58.85K by 61.44%. Apple's EBITDA was $-328M, beating the average prediction of $-86.113M by 280.59%. The company's net income was $-327M, missing the average estimation of $-387M by -15.46%. Apple's SG&A was $71.67M, beating the average forecast of $12.77M by 461.42%. Lastly, the company's EPS was $-0.0021, missing the average prediction of $-2.176 by -99.90%. In terms of the last quarterly report (Sep 2023), Allogene Therapeutics's revenue was $43K, beating the average analysts' forecast of $14.46K by 197.33%. The company's EBITDA was $-62.975M, beating the average prediction of $-2.892K by 2177458.78%. Allogene Therapeutics's net income was $-61.315M, missing the average estimation of $-98.715M by -37.89%. The company's SG&A was $17.04M, beating the average forecast of $3.14M by 443.14%. Lastly, the company's EPS was $-0.37, missing the average prediction of $-0.519 by -28.77%